Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C by Freedman, Neal D. et al.
Coffee Intake Is Associated with Lower Rates of Liver
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Higher coffee consumption has been associated inversely with the incidence of chronic liver
disease in population studies. We examined the relationship of coffee consumption with
liver disease progression in individuals with advanced hepatitis C–related liver disease.
Baseline coffee and tea intake were assessed in 766 participants of the Hepatitis C Antiviral
Long-Term Treatment against Cirrhosis (HALT-C) trial who had hepatitis C–related bridg-
ing fibrosis or cirrhosis on liver biopsy and failed to achieve a sustained virological response
to peginterferon plus ribavirin treatment. Participants were followed for 3.8 years for clinical
outcomes and, for those without cirrhosis, a 2-point increase in Ishak fibrosis score on
protocol biopsies. At baseline, higher coffee consumption was associated with less severe
steatosis on biopsy, lower serum aspartate aminotransferase (AST)/alanine aminotransferase
(ALT) ratio, alpha-fetoprotein, insulin, and homeostatic model assessment (HOMA2) score,
and higher albumin (P < 0.05 for all). Two hundred thirty patients had outcomes. Outcome
rates declined with increasing coffee intake: 11.1/100 person-years for none, 12.1 for less
than 1 cup/day, 8.2 for 1 to fewer than 3 cups/day, and 6.3 for 3 or more cups/day (P-trend 
0.0011). Relative risks (95% confidence intervals) were 1.11 (0.76-1.61) for less than 1
cup/day; 0.70 (0.48-1.02) for 1 to fewer than 3 cups/day; and 0.47 (0.27-0.85) for 3 or more
cups/day (P-trend  0.0003) versus not drinking. Risk estimates did not vary by treatment
assignment or cirrhosis status at baseline. Tea intake was not associated with outcomes.
Conclusion: In a large prospective study of participants with advanced hepatitis C–related
liver disease, regular coffee consumption was associated with lower rates of disease progres-
sion. (HEPATOLOGY 2009;50:1360-1369.)
Hepatitis C virus (HCV) infects approximately2.2% of the world’s population (includingmore than three million individuals in the
United States).1 Treatment with peginterferon and riba-
virin for 24-48 weeks clears virus and resolves chronic
hepatitis in approximately half of patients.2 The remain-
ing patients and patients ineligible for or unable to toler-
ate treatment have few additional options, such that
identification of modifiable risk factors for disease pro-
gression is a clinically important issue.
Coffee intake may have beneficial effects on the liver.
Increasing coffee consumption has been inversely associ-
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ated with liver enzyme concentrations, including alanine
aminotransferase (ALT), aspartate aminotransferase
(AST), and gamma-glutamyltransferase.3–8 In population
studies, among persons with unknown diagnosis of liver
disease, greater coffee intake has been associated with
lower risk of cirrhosis,6,9–12 chronic liver disease,13 and
hepatocellular carcinoma.14,15 Laboratory studies suggest
that several components of coffee, including caffeine,16–19
diterpenes,20 and polyphenols,21 may have beneficial ef-
fects on the liver. However, no studies have examined the
relationship between coffee consumption and progression
of liver disease among persons known to have advanced
hepatic fibrosis.
We prospectively examined the association of coffee
intake and liver disease progression in participants of the
Hepatitis C Antiviral Long-Term Treatment against Cir-
rhosis (HALT-C) trial, a large randomized controlled trial
evaluating the role of long-term peginterferon alfa-2a for
the prevention of disease progression in patients with
HCV-related bridging fibrosis and cirrhosis whose condi-
tion had failed to respond to peginterferon plus ribavirin
therapy.
Patients and Methods
Study Population. The design and results of the
HALT-C trial have been published.22 Randomized sub-
jects had detectable HCV RNA and met the following
criteria: failure to achieve a sustained virological response
with previous peginterferon/ ribavirin therapy; advanced
hepatic fibrosis on liver biopsy (Ishak stage  3); no his-
tory of hepatic decompensation or hepatocellular carci-
noma; and absence of defined exclusion criteria (such as
liver disease other than hepatitis C, uncontrolled medical
or psychiatric conditions). All participants were required
to have an ultrasound, computed tomography, or mag-
netic resonance imaging with no evidence of hepatic mass
lesions suspicious of hepatocellular carcinoma. Partici-
pants were randomized to low-dose maintenance therapy
(peginterferon alfa-2a 90 m weekly) or no treatment.
Liver biopsies were repeated 1.5 and 3.5 years after ran-
domization. All biopsies were reviewed in conference by a
panel of 12 hepatic pathologists. The Ishak scoring system
was used to assess inflammation (0-18) and fibrosis (0-
6).23 The homeostatic model assessment (HOMA2) score
of insulin resistance was calculated as previously de-
scribed.24 Treated and untreated participant data from
the randomized phase of the trial were combined, because
maintenance low-dose peginterferon therapy did not af-
fect clinical outcome or histological progression.22
Of 1050 randomized participants, we excluded 241
participants who did not complete the food frequency
questionnaire (FFQ), 1 participant with extreme caloric
intake (total energy intake more than two interquartile
ranges from the median), and 42 participants lacking fol-
low-up biopsies. After exclusions, our dataset included
766 participants.
Exposure Assessment. At study baseline, participants
completed the Block 98.2 FFQ (Block Data Systems, Berke-
ley, CA), which has been extensively validated.25,26 Partici-
pants were asked to report their typical frequency of intake
and portion size over the past year, using nine frequency
categories ranging from “never” to “every day” and four cat-
egories of portion size (1 cup, 2 cups, 3-4 cups, and 5
cups). One question assessed coffee consumption, and a sec-
ond question assessed black or green tea intake. Participants
also completed a second Block 98.2 FFQ approximately 13
months (median, 12.9 months; interquartile range, 12.3-
15.4 months) after randomization. We calculated typical in-
take (cups per day) from the questionnaire. For analysis, we
created categorical variables of coffee (never, 0 to 1, 1
to 3, and 3 cups/day) and tea intake (never, 0 to 1,
1 to 2, and 2 cups/day). Participants also completed a
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short-form 36-item quality of life questionnaire (SF-36)27 at
baseline.
Assessment of Outcomes. Participants were seen every
3 months during the study period. Complete blood
counts, liver chemistry panel, and alpha-fetoprotein
(AFP) were tested at each clinical site. Participants had at
least one ultrasound examination every 12 months. Pre-
defined clinical outcomes included ascites, Child-Tur-
cotte-Pugh score of at least 7 on two consecutive study
visits, liver disease–related death, hepatic encephalopathy,
hepatocellular carcinoma, spontaneous bacterial peritoni-
tis, or variceal hemorrhage; and for participants with
bridging fibrosis at baseline, a 2-point or more increase in
Ishak fibrosis score on either of the follow-up biopsies. All
outcome reports were reviewed by an Outcomes Review
Panel, consisting of three investigators from the partici-
pating clinical centers. Excluding hepatocellular carci-
noma (23 events) did not alter results (data not shown).
We present results for a combined endpoint, which included
both clinical outcomes and, for those with fibrosis at ran-
domization, a 2-point increase in Ishak fibrosis score. Results
for individual endpoints were similar (Fig. 1).
All details of this study were approved by the local
Institutional Review Board at each participating institu-
tion, and all participants gave written informed consent.
Statistical Analyses. Analyses were performed with
SAS release 9.1 (SAS Institute, Cary, NC). An alpha level
of less than 0.05 was considered statistically significant,
and all tests were two sided.
We tabulated baseline demographic, behavioral, and
clinical factors by categories of coffee (Table 1) or tea
intake (data not shown). Statistically significant variation
across categories of increasing coffee or tea intake was
assessed with the Mantel-Haenszel test for trend for cate-
gorical variables and the Jonckheere-Terpstra test for
trend for continuous variables.
Relative risks and 95% confidence intervals for the
association of coffee and tea intake and liver disease pro-
gression were calculated by use of Cox proportional haz-
ards regression.28 We calculated follow-up time in
person-years from baseline to first outcome, end of study,
or date of patient withdrawal. Linear trend tests across
increasing categories of coffee and tea intake were per-
formed by assigning participants the median intake for
their categories and entering that term as a continuous
variable in the regression model. We tested the propor-
tional hazards assumption by modeling interaction terms
of time and the trend variable for coffee or tea intake and
found no significant deviations.
We examined risk estimates from crude and multivar-
iate models that were adjusted for known and suspected
confounders, including age, baseline Ishak fibrosis score,
body mass index, education, sex, race and ethnicity, life-
time alcohol intake, pack-years of cigarette use, intake of
total energy, and coffee or tea with progression of liver
disease.
Possible effect modification by randomization group, cir-
rhosis at baseline, self-reported health, sex, use of alcohol or
cigarettes at baseline, hepatic steatosis grade, esophageal var-
ices, serum AFP levels, AST/ALT ratio, bilirubin, and albu-
min were assessed by stratification and formally tested by
including an interaction term between each stratifying vari-
able and continuous coffee intake in the model.
The concordance of reported coffee intake between the
two food frequency questionnaires was assessed by the
weighted kappa statistic. We also examined whether the
consistency of reported coffee intake across question-
naires affected the association coffee intake with liver dis-
ease progression. These analyses were restricted to those
who completed both questionnaires (n  633) and did
not have an outcome before completion of their second
questionnaire (n  586); follow-up time began at the date
of the second questionnaire. For analysis, a single variable
with mutually exclusive categories from intake reported
on each questionnaire was used.
Results
Coffee intake varied from zero to five or more cups per
day, with a median intake of one cup per day. At baseline,
higher coffee consumption was associated with male sex,
white race, higher lifetime alcohol and cigarette use, in-
creased tea consumption and total energy intake, lower
baseline HOMA2 score, lower fasting insulin levels,
higher log HCV RNA level, and less severe liver disease
(lower AFP levels, serum AST/ALT ratio, hepatic steato-
sis grade, and higher albumin), P  0.05 for all (Table 1).
We observed no association between coffee intake and
age, body mass index, cirrhosis status, diabetes, educa-
tional attainment, HCV genotype, Ishak inflammation
score, platelets, prothrombin time, or treatment group
(Table 1). We also examined the association of SF-36
quality of life domains with coffee intake. The physical
functioning score had no association with coffee intake
(P  0.78), although coffee drinkers tended to have
poorer general health (P  0.29) and vitality scores (P 
0.018) than nondrinkers. Among baseline variables exam-
ined, higher tea consumption was associated only with
total energy intake and coffee intake (data not shown).
During 2407 person-years of follow-up (median, 3.8
years per patient; interquartile range, 2.6-3.8 years), 230
individuals had a 2-point increase in fibrosis score from
baseline or a clinical outcome for liver disease. Combining
these endpoints, we observed an inverse association be-
tween coffee intake and liver disease progression (Table
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2). In crude models, the relative risk (RR) associated with
a one-cup-per-day increase in coffee consumption was
0.88 (95% confidence interval [CI], 0.79-0.98). In anal-
yses involving categorical variables, we found that indi-
viduals drinking three or more cups of coffee per day had
an RR of 0.56 (95%CI, 0.33-0.97) relative to non–coffee
drinkers. Across increasing categories of coffee consump-
tion, the P for trend was 0.0013. In multivariate models
adjusted for age, baseline Ishak fibrosis score, body mass
index, education, sex, race, and ethnicity, lifetime alcohol
intake, pack-years of cigarette use, tea intake, and total
energy intake, we observed similar risk estimates to those
from crude models. Relative to nondrinkers, drinkers of
three or more cups of coffee per day had an RR of 0.47
(95%CI, 0.27-0.85) for reaching an endpoint indicative
of disease progression.




P for Trend*Nondrinkers >0 to <1 cups/day >1 to <3 cups/day >3 cups/day
Number in cohort 131 222 324 89
Treatment group, no. (%) 63 (48.1%) 113 (50.9%) 166 (51.2%) 42 (47.2%) 0.925
Coffee intake (cups/day), median (IQR) 0 0.29 (0.03–0.5) 2 (1–2) 3.5 (3.5–3.5)
Age, years, median (IQR) 48 (45–53) 50 (46–54) 50 (46–54) 49 (46–53) 0.30
Sex, female, no. (%) 47 (35.9%) 66 (29.7%) 88 (27.2%) 16 (18.0%) 0.007
General health score from SF-36, median (IQR) 62 (37–77) 64 (47–77) 62 (42–77) 57 (40–67) 0.29
Physical functioning score from SF–36, median (IQR) 85 (50–95) 90 (61–100) 85 (60–95) 87.5 (67.5–95.0) 0.78
Vitality score from SF-36, median (IQR) 55 (35–80) 60 (45–75) 55 (40–70) 50 (35–65) 0.018
Race/ethnicity
Caucasian, no. (%) 90 (68.7%) 141(63.5%) 262 (80.9%) 82 (92.1%) 0.0001
African American, no. (%) 30 (22.9%) 53 (23.9%) 35 (10.8%) 1 (1.1%)
Hispanic, no. (%) 6 (4.6%) 23 (10.4%) 23 (7.1%) 3 (3.4%)
Other, no. (%) 5 (3.8%) 5 (2.3%) 4 (1.2%) 3 (3.4%)
Education†
High school or less, no. (%) 41 (31.3%) 69 (31.1%) 101 (31.3%) 36 (40.5%) 0.21
Some post high school, no. (%) 49 (37.4%) 95 (42.8%) 133 (41.2%) 33 (37.1%)
Completed college, no. (%) 41 (31.3%) 58 (26.1%) 89 (27.6%) 20 (22.5%)
Lifetime alcohol consumption, no. of drinks,
median (IQR) 4117 (438–16,445) 5050 (768–16,318) 8875 (1463–22,877) 18,083 (3854–37,944) 0.0001
Pack-years of cigarettes, median (IQR) 4.0 (0–15.0) 3.0 (0–14.5) 13.5 (1.4–26.0) 23.5 (10.0–37.0) 0.0001
Green and black tea intake, cups per day,
median (IQR) 0.08 (0–0.57) 0.14 (0.01–0.5) 0.14 (0.01–0.79) 0.11 (0.01–0.57) 0.029
Total energy, Kcal, median (IQR) 1959 (1289–2612) 1811 (1292–2349) 1907 (1399–2540) 2302 (1554–2809) 0.019
Body mass index, median (IQR) 29.2 (25.9–32.4) 29.1 (26.4–32.3) 29.0 (26.2–32.8) 28.7 (25.7–31.8) 0.54
Diabetes, glucose  126, no. (%) 42 (32.1%) 47 (21.2%) 61 (18.8%) 20 (22.5%) 0.107
Baseline HOMA2,† median (IQR) 5.7 (3.7–7.1) 4.3 (2.9–6.7) 4.1 (3.0–6.5) 4.0 (2.5–6.5) 0.001
Insulin,† median (IQR) 43.9 (26.7–79.6) 34.1 (22.3–55.0) 33.4 (23.2–51.2) 31.4 (19.2–53.0) 0.002
AFP, ng/mL, median (IQR) 9.7 (5.2–18.5) 11.1 (5.9–23.0) 7.5 (5.0–15.3) 6.2 (4.0–10.4) 0.0001
AST, median (IQR) 71 (46–108) 77 (55–128) 70 (50.5–107) 60 (43–96) 0.021
ALT, median (IQR) 82 (53–116) 94 (59–141) 88 (60–133) 72 (58–122) 0.77
AST/ALT ratio, median (IQR) 0.86 (0.71–1.07) 0.88 (0.71–1.07) 0.79 (0.66–1.00) 0.75 (0.63–0.86) 0.0001
Albumin, g/dL, median (IQR) 3.8 (3.6–4.1) 3.9 (3.5–4.1) 4.0 (3.7–4.2) 4.0 (3.8–4.2) 0.0001
Bilirubin, mg/dL, median (IQR) 0.7 (0.5–0.9) 0.8 (0.6–1.0) 0.7 (0.5–1.0) 0.6 (0.5–0.8) 0.053
Platelets, 1000/mm3, median (IQR) 159 (106–220) 146 (112–196) 163 (119–203) 161 (127–215) 0.25
Prothrombin time, INR, median (IQR) 1.0 (1.0–1.1) 1.0 (1.0–1.1) 1.0 (1.0–1.1) 1.0 (1.0–1.1) 0.188
Log HCV RNA level, median (IQR) 6.4 (6.1–6.7) 6.4 (6.1–6.8) 6.5 (6.2–6.8) 6.7 (6.3–6.9) 0.034
HCV genotype 1, no. (%) 123 (93.9%) 202 (91.0%) 312 (96.3%) 79 (88.8%) 0.80
Cirrhosis on biopsy, no. (%) 57 (43.5%) 103 (46.4%) 143 (44.1%) 28 (31.5%) 0.073
Hepatic steatosis
Grade 0, no. (%) 16 (12.2%) 34 (15.3%) 65 (20.1%) 17 (19.1%) 0.047
Grade 1, no. (%) 59 (45.0%) 89 (40.1%) 130 (40.1%) 37 (41.6%)
Grade 2, no. (%) 39 (29.8%) 69 (31.1%) 105 (32.4%) 25 (28.1%)
Grade 3 or 4, no. (%) 17 (13.0%) 30 (13.5%) 24 (7.4%) 10 (11.2%)
Ishak inflammation score, median (IQR) 7 (6–9) 8 (6–9) 8 (6–9) 7 (6–9) 0.51
Esophageal varices,† no. (%) 35 (27.1%) 67 (30.5%) 84 (26.6%) 16 (18.2%) 0.068
IQR, interquartile range; no., number.
*Mantel-Haenszel test for trend for categorical variables. Jonckheere-Terpstra test for trend for continuous variables and race/ethnicity.
†Data not available for all participants: Education available for 765 participants; Esophageal varices for 753 participants; Insulin and Homa2 score for 593
participants; Pack-years of cigarettes for 757 participants.
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In contrast to coffee intake, no association between
black and green tea intake and liver disease progression
was observed. In crude models, the RR associated with a
one cup per day increase in tea intake was 1.03 (95%CI,
0.91-1.18); the RR from multivariate adjusted models
was 1.02 (95%CI, 0.90-1.17) (Table 3).
In addition to the baseline FFQ, 633 participants also
completed a second FFQ approximately 13 months later.
Participants reported similar coffee intakes on both FFQs
with a weighted kappa  0.59, which indicates good
agreement. The test of symmetry was not rejected (P 
0.92), indicating that there was no systematic increase or
decrease in coffee consumption between the two time
points. In analyses restricted to events that occurred after
administration of the second FFQ (n  599), we ob-
served similar associations between coffee intake and pro-
gression of liver disease, whether we used coffee intake
reported on the baseline or the subsequent FFQ. From
multivariate adjusted models, an increase of one cup of
coffee per day on the first FFQ was associated with an RR
of 0.84 (95%CI, 0.72-0.97). Similarly, an increase of one
cup of coffee per day on the second FFQ was associated
with an RR of 0.78 (95%CI, 0.67-0.92). Relative to non-
drinkers on both FFQs, coffee drinkers reporting up to
three cups of coffee per day on either FFQ had an RR of
0.79 (95%CI, 0.50-1.24), drinkers of three or more cups
of coffee per day on either FFQ had an RR of 0.60
(95%CI, 0.30-1.19), and drinkers of three or more cups
of coffee per day on both FFQs had an RR of 0.38
(95%CI, 0.14-1.03).
We examined whether risk estimates for coffee intake
and liver disease progression varied by treatment group,
cirrhosis status at baseline, type of outcome, sex, current
alcohol and cigarette use, and markers of liver disease
severity, presenting results for drinking three or more
cups per day relative to nondrinking (Fig. 1). Risk esti-
mates did not vary by treatment group (P for interac-
tion  0.16). We observed an RR of 0.51 (95%CI, 0.19-
1.39) in the active treatment group (112 events) and 0.45
(95%CI, 0.22-0.95) in the control group (118 events)
Table 2. Association of Baseline Coffee Intake with Liver Disease Progression in 766 Participants of the HALT-C Trial
RR per Cup/Day Nondrinkers >0 to <1 Cups/Day >1 to <3 Cups/Day >3 Cups/Day P for Trend
Cohort, person-years (%) 404 (16.8) 678 (28.2) 1039 (43.2) 286 (11.9)
Cases, no. (%) 45 (19.6) 82 (35.7) 85 (37.0) 18 (7.8)
Crude RR (95% CI) 0.88 (0.79–0.98) 1.00 (ref) 1.09 (0.76–1.57) 0.73 (0.51–1.05) 0.56 (0.33–0.97) 0.0013
Multivariate adjusted RR* 0.85 (0.76–0.96) 1.00 (ref) 1.11 (0.76–1.61) 0.70 (0.48–1.02) 0.47 (0.27–0.85) 0.0003
Multivariate RR additionally adjusted
for general health score†
0.85 (0.76–0.96) 1.00 (ref) 1.12 (0.77–1.63) 0.70 (0.48–1.02) 0.47 (0.27–0.84) 0.0003
RR additionally adjusted for markers
of liver function‡
0.91 (0.81–1.02) 1.00 (ref) 1.15 (0.78–1.70) 0.87 (0.58–1.29) 0.66 (0.36–1.19) 0.041
CI, confidence interval; no., number; RR, relative risk.
*Adjusted for age, body mass index, education, ethnicity, sex, baseline Ishak fibrosis score, total energy intake, lifetime alcohol intake, pack-years of cigarette use,
and tea intake.
†Adjusted for age, body mass index, education, ethnicity, sex, baseline Ishak fibrosis score, total energy intake, lifetime alcohol intake, pack-years of cigarette use,
tea intake, and SF-36 general health score.
‡Adjusted for age, body mass index, education, ethnicity, sex, baseline Ishak fibrosis score, total energy intake, lifetime alcohol intake, pack-years of cigarette use,
tea intake, SF-36 general health score, albumin, AST/ALT ratio, bilirubin, esophageal varices, hepatic steatosis grade, and platelets.
Table 3. Association of Baseline Tea Intake with Liver Disease Progression in 766 Participants of the HALT-C Trial
RR per Cup/Day Nondrinkers >0 to <1 Cups/Day >1 to <2 Cups/Day >2 Cups/Day P for Trend
Cohort, person-years (%) 456 (18.9) 1441 (59.9) 335 (13.9) 175 (7.3)
Cases, no. (%) 39 (17.0) 146 (63.5) 27 (11.7) 18 (7.8)
Crude RR (95% CI) 1.03 (0.91–1.18) 1.00 (ref) 1.19 (0.84–1.70) 0.94 (0.58–1.54) 1.21 (0.69–2.11) 0.672
Multivariate adjusted RR* 1.02 (0.90–1.17) 1.00 (ref) 1.24 (0.87–1.79) 0.96 (0.59–1.58) 1.19 (0.67–2.10) 0.576
Multivariate RR additionally adjusted
for general health score†
1.02 (0.89–1.16) 1.00 (ref) 1.24 (0.87–1.78) 0.94 (0.57–1.55) 1.16 (0.65–2.05) 0.498
RR additionally adjusted for markers
of liver function‡
1.08 (0.94–1.24) 1.00 (ref) 1.09 (0.75–1.58) 0.82 (0.49–1.37) 1.54 (0.85–2.78) 0.982
CI, confidence interval; no., number; RR, relative risk.
*Adjusted for age, body mass index, education, ethnicity, sex, baseline Ishak fibrosis score, total energy intake, lifetime alcohol intake, pack-years of cigarette use,
and coffee intake.
†Adjusted for age, body mass index, education, ethnicity, sex, baseline Ishak fibrosis score, total energy intake, lifetime alcohol intake, pack-years of cigarette use,
coffee intake, and SF-36 general health score.
‡Adjusted for age, body mass index, education, ethnicity, sex, baseline Ishak fibrosis score, total energy intake, lifetime alcohol intake, pack-years of cigarette use,
coffee intake, SF-36 general health score, albumin, AST/ALT ratio, bilirubin, esophageal varices, hepatic steatosis grade, and platelets.
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relative to nondrinkers. Estimates also did not vary by
cirrhosis status. For those starting with bridging fibrosis
(146 events), the RR was 0.46 (95%CI, 0.23-0.91),
whereas for those starting with cirrhosis (84 events), it was
0.44 (95%CI, 0.14-1.38); P for interaction  0.39. Risk
estimates were similar for the development of clinical out-
comes (0.54; 95%CI, 0.23-1.26) and for a 2-point in-
crease on Ishak score (0.34; 0.15-0.75). Risk estimates
were similar in men and women (0.56; 95%CI, 0.29-
1.09; in women: 0.14; 95%CI, 0.03-0.72) and did not
vary by use of alcohol (P for interaction  0.48) or ciga-
rettes (P for interaction  0.40) at baseline.
We also observed similar risk estimates for those with
above median values and below median values of AFP,
albumin, AST/ALT ratio, bilirubin, hepatic steatosis
grade, or platelets, and for those with and without esoph-
ageal varices at baseline (P for interaction  0.2 for all)
(Fig. 1). Additionally, adjusting for these markers of liver
disease severity attenuated the association between coffee
intake and liver disease progression (0.66; 95%CI, 0.36-
1.19; P-trend across categories  0.041; without adjust-
ment for these markers: RR, 0.47; 95%CI, 0.27-0.85;
P-trend  0.0003; Table 2).
Adjustment for SF-36 general health score did not
meaningfully alter risk estimates (0.47; 95%CI,
0.27-0.84; Table 2). Risk estimates were similar in those
with a less than the median SF-36 general health score
(RR, 0.39; 95%CI, 0.19-0.77; 126 events) and those with
a greater than median general health score (RR, 0.76;
95%CI, 0.27-2.10; 96 events); P for interaction  0.29
(Fig. 1). Results for other SF-36 quality of life domains
were similar (data not shown).
Finally, we examined whether risk estimates for coffee
intake varied after adjustment for biochemical markers of
insulin resistance and inflammation. Adjustment for dia-
betes or glucose as a continuous variable did not affect risk
estimates (data not shown). In contrast, in models re-
stricted to 593 participants with measured insulin, addi-
tion of insulin or HOMA2 score attenuated risk estimates
slightly (three cups per day or more relative to nondrink-
ing without insulin or HOMA2 score in the model: 0.48;
95%CI, 0.25-0.93; with insulin in the model: 0.56;
95%CI, 0.28-1.10; with HOMA2 in the model: 0.55;
95%CI, 0.28-1.08). With regards to inflammation, re-
sults did not change after adjustment for Ishak inflamma-
Fig. 1. Subgroup analysis of the
association of baseline coffee intake
with liver disease progression in the
HALT-C trial. Relative risk estimates
shown are for drinking three or more
cups of coffee per day relative to
nondrinking and are adjusted for
age, body mass index, education,
ethnicity, sex, baseline Ishak fibrosis
score, total energy intake, lifetime
alcohol intake, pack-years of ciga-
rette use, and tea intake. Black di-
amond indicates the overall point
estimate. Black circles and squares
represent the point estimate for
each indicated subgroup. Horizontal
lines represent 95% confidence in-
tervals (CI). The solid vertical line
indicates a relative risk of 1. P val-
ues are for the interaction between
coffee intake and each stratifying
variable and are taken from the
Wald-test for the cross-product term
of each stratifying variable and con-
tinuous coffee intake. CI, confidence
interval.
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tion score at baseline (HR for three or more cups per day
relative to nondrinking: 0.46; 95%CI, 0.26-0.83).
Discussion
In this prospective study of patients with chronic hep-
atitis C and advanced liver disease who had failed to
achieve a sustained virological response with peginter-
feron plus ribavirin treatment, we observed an inverse
association between coffee intake and liver disease pro-
gression. Drinkers of three or more cups of coffee per day
had 53% lower risk of liver disease progression than non–
coffee drinkers. Results were consistent for coffee intake
assessed on the baseline questionnaire and coffee intake
assessed on a second questionnaire 13 months later. Re-
sults were also similar for those with both bridging fibrosis
and cirrhosis at baseline. In contrast to coffee, we ob-
served no association with consumption of black or green
tea.
This is the first study to address the association be-
tween coffee intake and liver disease progression. Previous
studies in persons with unknown liver disease, however,
have observed inverse associations between coffee intake
and the risk of cirrhosis,6,9–12 chronic liver disease,13 and
hepatocellular carcinoma.14,15 A limitation of these and
other previous studies has been the inclusion of persons
without liver disease, who were not at risk of its compli-
cations. Inverse associations in these studies could simply
reflect a lack of coffee drinking in persons with advanced
liver disease. In contrast to these studies, all patients in the
HALT-C trial had advanced liver disease documented by
liver biopsy. Furthermore, all patients in HALT-C had
chronic hepatitis C; patients with other causes of liver
disease were excluded. Hence, the trial participants were
homogeneous for the cause and stage of liver disease. This
design and the ability to assess a large number of poten-
tially confounding factors rendered this trial an excellent
vehicle for studying risk factors for liver disease progres-
sion.
In support of our prospective findings regarding liver
disease progression, we found that coffee drinking at base-
line was associated with better status for many markers of
liver disease and portal hypertension, including lower
AFP levels, serum AST/ALT ratio, hepatic steatosis grade,
and higher albumin. Previous studies from the United
States, Japan, and Italy3–8 reported similar results in cross-
sectional comparisons of coffee intake and liver disease
markers (gamma-glutamyltranspeptidase, ALT, AST,
and the AST/ALT ratio).
Symptoms of poor health may cause individuals to
decrease their coffee intake, perhaps resulting in the ob-
served association between coffee intake and reduced dis-
ease progression. In our study, however, individuals with
lower general health and vitality scores actually reported
drinking more coffee than individuals with higher scores.
Also, including SF-36 health scores in risk models did not
alter results. We observed no evidence for an association
between reduced coffee consumption on the second FFQ,
relative to the first, and subsequent disease outcomes.
Risk estimates were also similar for those with fibrosis and
cirrhosis at baseline. Although coffee intake was associ-
ated inversely with several markers of severe liver disease at
baseline, risk estimates appeared similar in those with
higher and lower values for these markers. Including these
markers in the models attenuated risk estimates, but evi-
dence for an inverse association with coffee intake per-
sisted even after adjustment.
Individuals who drank coffee had higher lifetime alco-
hol consumption and cigarette use and also were more
likely to be current alcohol drinkers and cigarette smokers
than non–coffee drinkers (data not shown). Adjustment
for lifetime or current alcohol consumption or cigarette
use did not affect risk estimates for the association of
coffee and liver disease progression. Risk estimates for
coffee and liver disease progression were similar in both
individuals who smoked cigarettes or drank alcohol at
baseline and those who did not. Finally, lifetime or cur-
rent use of alcohol or cigarettes was not associated with
liver disease progression (data not shown). Together,
these results suggest that the association between coffee
and liver disease progression observed in this study was
independent of alcohol intake and cigarette smoking.
Coffee intake could be a marker of socioeconomic sta-
tus or another unmeasured or poorly measured exposure.
With regard to socioeconomic status, coffee intake did
not vary by educational attainment. In addition, partici-
pants were part of a National Institutes of Health–funded
clinical trial and as such received excellent medical care
during the study, regardless of their education or socio-
economic status. Inverse associations between coffee in-
take and liver disease have been observed in diverse
geographic regions, each with different risk factors for
liver disease, arguing against coffee as a surrogate for an-
other protective factor. Coffee intake is also not generally
considered to be part of a healthy lifestyle. Nevertheless,
as in all observational analyses, observed associations in
this study could be attributable to unmeasured or poorly
measured confounders.
Coffee intake might protect against liver disease via
several mechanisms. Coffee intake has been associated
with a decreased risk of type 2 diabetes,29 and diabetes has
been associated with liver disease,30 suggesting that coffee
intake could affect liver disease by modulating insulin
sensitivity. Supporting this mechanism, the coffee con-
stituent chlorogenic acid has been shown to inhibit activ-
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ity of glucose-6-phosphatase,31 an important regulator of
blood glucose levels.32 In our study, we observed an in-
verse association between coffee intake and serum insulin
levels and baseline HOMA2 score, but no association
with serum glucose. Addition of insulin or HOMA2 score
to the models slightly attenuated the results for coffee,
suggesting that the effect of coffee may act, at least in part,
through insulin signaling. Coffee intake could also act by
reducing inflammation, because the inflammatory re-
sponse to liver injury is thought to cause fibrosis and
cirrhosis.33 Several studies have found evidence for an
inverse association between coffee intake and mortality
from other inflammation-related diseases34,35 as well as
surrogate markers of inflammation such as C-reactive
protein,36 although not all studies are consistent.37 In our
study, coffee intake was not associated with hepatic in-
flammation at baseline, and adjusting for inflammation
score did not affect risk estimates. Finally, coffee could act
by reducing oxidative stress, which may play a role in
hepatic damage and disease progression.38
Coffee contains more than 1000 chemical compounds.
The most studied constituent is caffeine, which has po-
tent pharmacological effects and is present in coffee at
high amounts. In a previous study, the association be-
tween caffeine and ALT levels was stronger than that be-
tween coffee and ALT levels.7 In addition, caffeine has
been shown to inhibit hepatic carcinogenesis in rats39 and
transforming growth factor-beta signaling in rat hepato-
cytes.17 However, the association of other caffeinated bev-
erages (including tea and soft drinks) with liver disease has
been inconsistent, even in populations who consume
large quantities of tea, such as in Japan.6,8,10,40–42 We
observed no association with tea intake, although tea,
which contains lower concentrations of caffeine than cof-
fee, was consumed less frequently. In addition to caffeine,
coffee provides a rich source of bioactive compounds in-
cluding diterpenes20 and polyphenols.21 Future work is
needed to identify bioactive components in coffee and
determine their effect in vivo.
Our study benefited from a prospective design, assess-
ment of diet at two time points, comprehensive assess-
ment of clinical and histological features, and careful
assessment of clinical and histological endpoints. Limita-
tions include lack of information on decaffeinated coffee,
soft drinks, and coffee brewing methods. As an observa-
tional study, the association observed with coffee intake
could reflect another exposure or could have been the
result of, rather than the cause of, liver disease progres-
sion. Also, the SF-36 questionnaire assessing self-reported
health may not accurately assess gastrointestinal symp-
toms that may affect coffee intake. Our data on coffee
consumption was also self-reported and may not accu-
rately reflect consumption over the entire time period of
liver disease progression. Finally, individuals in this study
were hepatitis C positive, had advanced chronic liver dis-
ease, and did not respond to standard of care therapy. As
such, our findings may not be generalizable to healthier
populations. Nevertheless, because individuals who do
not respond to standard care therapy represent a sizable
proportion of hepatitis C–positive individuals, these find-
ings are of potential importance to a large number of
individuals worldwide.
In summary, in a prospective study of individuals with
hepatitis C and bridging fibrosis or cirrhosis at baseline,
we found a significant inverse association between regular
coffee intake and liver disease progression.
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